CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced the initiation of a study in large animals for its 3D bioprinted regenerative breast implant program, addressing the $2.8 billion global breast implant market. “This study is a quantum leap in the development of 3D bioprinted regenerative breast implants,” said Yehiel Tal, CollPlant’s Chief Executive Officer.  “We believe that our regenerative breast implants will address safety challenges associated with...